MDACC Study No:2011-0847 ( NCT No: NCT01603212)
Title:Systemic Therapy of Metastatic Melanoma with Multidrug Regimen Including Interferon, Interleukin-2 and BRAF Inhibitor
Principal Investigator:Rodabe N. Amaria
Treatment Agent:Interferon alfa 2b; Interleukine 2; PLX-4032
Study Status:Closed
Study Description:The goal of the Phase I part of this clinical research study is to find the
highest tolerable dose of vemurafenib and Aldesleukin (interleukin-2) that can
be given in combination with interferon alfa-2b in patients with advanced or
metastatic melanoma. The safety of this combination will also be studied.

The goal of Phase II is to learn if this study drug combination can help to
control advanced or metastatic melanoma.
Hide details for General InformationGeneral Information

Disease Group:Melanoma
Phase of Study:Phase I/Phase II
Treatment Agents:Interferon alfa 2b
Interleukine 2
Treatment Location:Only at MDACC
Estimated Length of Stay in Houston:
Supported By:N/A
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Rodabe N. Amaria
Dept:Melanoma Medical Oncology
For Clinical Trial Enrollment:713-792-2921
For General Questions about Clinical Trials:800-392-1611 (in U.S.A.) 713-792-6161 (outside U.S.A.)

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults